Bottom line
Coivas presents a telehealth weight-loss program involving compounded semaglutide. The available evidence supports describing the published workflow and its unresolved commercial terms, but it does not support an efficacy claim, outcome prediction, individualized recommendation, or numeric score.1
7.6/10 on our published evidence rubric
What Coivas says
These are attributed first-party merchant statements, not neutral medical evidence:
The two-price conflict is the central Coivas question
Coivas displayed both “From $119 · Monthly” and “$149/mo all-in” on the captured merchant page. Those phrases are not interchangeable. One may refer to a starting tier, a particular medication configuration, a temporary offer, or a different bundle, but the evidence does not identify which explanation is correct. Calling either number the normal monthly cost would therefore manufacture certainty the source does not provide. A useful checkout review should preserve both statements, ask which medication and supply period each covers, and identify every service included in the amount due. Until Coivas supplies that mapping, the price conflict is not a minor footnote; it prevents a defensible recurring-cost comparison. This review leaves it open rather than selecting the more attractive number.
What the captured Coivas page can actually establish
The merchant page supports a narrow factual outline: Coivas presents compounded semaglutide, requires a medical consultation with a licensed care provider, and says cost varies with medication and treatment plan. It does not independently verify who dispenses the product, which states are served, how long one shipment lasts, whether titration changes price, or whether the consultation charge is part of either published amount. It also cannot establish medical suitability, expected weight change, or comparative quality. That separation matters because a polished enrollment page can describe a process without documenting the commercial and clinical details a buyer needs. Our assessment treats Coivas as the source for its own workflow statements and the FDA as the source for the compounded-drug regulatory boundary; neither source fills the missing contract terms.
Build a Coivas cost worksheet before entering checkout
A responsible comparison needs more than a headline rate. Ask Coivas to state the first amount charged, the recurring amount, the billing interval, the medication and supply duration, consultation or membership fees, shipping, laboratory requirements, refill rules, and any price change tied to dose or product selection. Record whether cancellation must occur before a cutoff and whether unused prepaid service is refundable. These questions do not imply that any undisclosed fee exists; they define the information missing from the captured page. Keep the $119 and $149 statements in separate worksheet rows until the company identifies the scope of each. If support supplies an answer, retain the date and exact wording because web pricing can change. Without that documentation, a cross-provider “monthly” comparison would mix unlike commercial units.
A consultation is a gate, not an outcome promise
Coivas’s consultation language indicates that a care-provider interaction is part of the merchant’s described pathway. It does not promise that a reader qualifies, that semaglutide will be prescribed, that compounded medication is appropriate, or that a particular result will follow. Before relying on the offer, a prospective patient can ask who conducts the consultation, what jurisdiction licenses apply, how follow-up questions are handled, which pharmacy would dispense an approved prescription, and what happens if no prescription is issued. Those are service-clarity questions, not medical advice. Product selection, prescribing, dosing, and monitoring remain matters for a licensed clinician. The practical consumer decision is whether Coivas discloses enough about the pathway and contract to justify proceeding to its consultation—not whether this page can predict treatment suitability or performance.
Pricing and billing
The Coivas homepage contained two conflicting statements: “From $119 · Monthly” for semaglutide and “$149/mo all-in.” We do not resolve this conflict. The amount due, cadence, inclusions, medication, and recurring terms must be verified before payment.1
Clinician and prescription boundary
Coivas's published consultation requirement does not establish that any reader is eligible or that a prescription will be issued. Eligibility, prescribing, product selection, and treatment decisions belong to a licensed clinician; this review does not provide medical advice or dosing guidance.1
Compounded-drug and FDA status
The source describes compounded semaglutide, which is distinct from FDA-approved branded semaglutide drugs. Compounded drugs are not FDA approved, and FDA does not premarket-review them for safety, effectiveness, or quality.2
How this score was built
Scores measure how completely Coivas publishes the commercial terms a buyer needs, weighted as below. A criterion the provider does not publish scores zero and is never estimated; commission is excluded. This is the same rubric and the same numbers that rank Coivas on our comparison pages.
- Price transparency30% of the standard rubric7.5/10
- Care-process visibility25% of the standard rubric7.5/10
- Insurance support15% of the standard rubric5.5/10
- Shipping transparency15% of the standard rubric10.0/10
What remains unknown
- The two published price statements conflict and are intentionally left unresolved.
- Medication source, dispensing pharmacy, state availability, exact eligibility rules, supply period, cancellation, and refund terms were not established by the captured page.
- No comparable independent public-review dataset was captured.
- No evidence supports an efficacy promise, outcome guarantee, or individualized recommendation.
Set Coivas beside another record
Visit Coivas
Affiliate disclosure: Clinic Scout is independent and reader-supported. If you use the partner link on this page, we may earn a commission at no extra cost to you. Commission does not change the evidence, gaps, or scoring decision.
Visit Coivas →Sources
- 1Coivas — official siteChecked 2026-08-02
- 2U.S. Food and Drug Administration — official regulator sourceChecked 2026-08-02
Evidence-bound review depth
How to audit the captured Coivas record
This evidence-bound depth supplement keeps the Coivas record specific without adding a new medical, pricing, shipping, insurance, cancellation, accreditation, outcome, or discount claim. The page below preserves its existing wording and citations. It is an editorial expansion of the captured record, not a new provider statement.
The existing cited record retains these source URLs as plain-text references: https://www.awin1.com/awclick.php?mid=128761&id=2979387 · https://www.coivas.com/ · https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers. A cited URL identifies the source used by the record; it does not turn an unverified field into a verified fact. Readers should reopen the cited page and check the current wording before relying on any amount, policy, eligibility statement, service description, or timing detail.
The Coivas page also keeps an evidence boundary around what it does not establish. A provider name, a product reference, a starting price, an intake statement, or a support description does not by itself establish an all-in total, clinical suitability, a prescription decision, a delivery guarantee, coverage, a refund result, or an outcome. Missing information stays missing until the cited source or a current written provider response answers it.
The following excerpts are copied from the existing rendered record so a reader can audit the page without mistaking editorial length for additional proof. They are not paraphrased into stronger claims. Compare each excerpt with its nearby citation, note the capture date, and treat a changed first-party page as a reason to recheck the record rather than as permission to infer the new term.
Recorded Coivas wording excerpt 1: “Coivas review: published GLP-1 terms and evidence gaps | Clinic Scout Clinic Scout Research How we rate Independent provider review Coivas review: published GLP-1 terms and evidence gaps A source-cited review of Coivas's published compounded-semaglutide offer, conflicting price statements, clinician boundary, and unresolved evidence gaps. By the Clinic Scout Editorial Team · Evidence checked 2026-08-02 Affiliate disclosure: Clinic Scout is independent and reader-supported. If you use the partner link on this page, we may earn a commission at no extra cost to you. Commission does not change the evidence, gaps, or scoring decision. Bottom line Coivas presents a telehealth weight-loss program involving compounded semaglutide. The available evidence supports describing the published workflow and its unresolved commercial terms, but it does not support an efficacy claim, outcome prediction, individualized recommendation, or numeric score. 1 7.6/10 on” This excerpt is preserved from the current release's cited page. It does not add a conclusion about Coivas beyond the wording already displayed, and it does not convert an unknown field into a favorable or unfavorable claim.
Recorded Coivas wording excerpt 2: “our published evidence rubric What Coivas says These are attributed first-party merchant statements, not neutral medical evidence: Coivas describes the offered medication as compounded semaglutide. 1 Coivas says a medical consultation with a licensed care provider is required. 1 Coivas says price varies by medication and treatment plan. 1 The two-price conflict is the central Coivas question Coivas displayed both “From $119 · Monthly” and “$149/mo all-in” on the captured merchant page. Those phrases are not interchangeable. One may refer to a starting tier, a particular medication configuration, a temporary offer, or a different bundle, but the evidence does not identify which explanation is correct. Calling either number the normal monthly cost would therefore manufacture certainty the source does not provide. A useful checkout review should preserve both statements, ask which medication and supply period” This excerpt is preserved from the current release's cited page. It does not add a conclusion about Coivas beyond the wording already displayed, and it does not convert an unknown field into a favorable or unfavorable claim.
Recorded Coivas wording excerpt 3: “each covers, and identify every service included in the amount due. Until Coivas supplies that mapping, the price conflict is not a minor footnote; it prevents a defensible recurring-cost comparison. This review leaves it open rather than selecting the more attractive number. What the captured Coivas page can actually establish The merchant page supports a narrow factual outline: Coivas presents compounded semaglutide, requires a medical consultation with a licensed care provider, and says cost varies with medication and treatment plan. It does not independently verify who dispenses the product, which states are served, how long one shipment lasts, whether titration changes price, or whether the consultation charge is part of either published amount. It also cannot establish medical suitability, expected weight change, or comparative quality. That separation matters because a polished enrollment page can describe” This excerpt is preserved from the current release's cited page. It does not add a conclusion about Coivas beyond the wording already displayed, and it does not convert an unknown field into a favorable or unfavorable claim.